Mitochondrial DNA Mutations

Until recently, mitochondrial genetics and disease were well known. These are caused by defects in mitochondrial DNA (mtDNA). Outside of mainstream genetics it is often viewed as something of an oddball.Mitochondria are present and present in all nucleated cells.Main producer of cellular ATP by oxidation

Phosphorylation (OXPHOS) involved in the electron transport respiratory chain (complexes I-IV)and ATP synthase (complex V). mitochondria are the only place where extrachromosomal DNA resides inside cells (excluding plant chloroplasts), and they arenuclear DNA and mitochondrial genome.

Mitochondria are key components of all nucleated cells. Therefore, it is not surprising that mtDNA disorders affect many tissues and have highly variable clinical presentations. This diversity creates difficulties defining the impact of mtDNA mutations on humans.However, in health, a stratification of clinical features takes place. The next group defines the scope of the problem.Classic mtDNA syndrome, clinical syndrome

Mutations in mtDNA, involvement in common disease phenotypes, high risk of mtDNA as a predisposing factor for common diseases and aging.

Defining and diagnosing the clinical features of mtDNA diseases remains a major challenge, but so does the development of effective therapies.Treatment is a difficult hurdle, even for experimental scientists. However, there are important issues related to the clinical management of patients, many of these issues have been discussed recently104. Early detection of treatable symptoms is important. Mutation levels in mitochondrial DNA can be manipulated by exercise. not present in healthy people

Exercise (deconditioning) leads to overall reduction Mitochondrial enzyme activity during endurance Enzyme activity increases with training. weight training or muscle necrosis stimulates uptake incorporate SATELLITE CELLS into existing muscle fibers. A new way to treat mitochondrial diseases. polyploidy properties of the mitochondrial genome, heteroplasmic phenomena, this is not possible potentially therapeutic nucleic acids organelles by mitochondrial transfection and slow realization of suitable animal models .MtDNA diseases are a major concern in the development of gene-based therapeutics. Still a few

strategies aimed at restoring mitochondrial function by compensating for genetic defects, or direct manipulation of mutant mtDNA levels

considered.